Perfuze
PrivateLast Round
Series A
Extension
Mar 13, 2025
Total Funding Raised
$76.39M
Company Overview
Perfuze is a medical device company that develops catheter-based aspiration technology for the treatment of acute ischemic stroke.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Perfuze Comparables
Compare Perfuze with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anaconda Biomed S.L. | 92% | |
| MIVI Neuroscience | 89% | |
| RapidPulse | 89% |
Perfuze Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Mar 13, 2025 | ||||
| Series A Extension | Mar 13, 2024 | ||||
| Series A | Feb 9, 2022 | ||||
| Seed | Jan 29, 2019 |
Key People
Founding team and executive leadership
Perfuze Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series A Extension, Series A |
| SV Health Investors | Series A Extension, Series A |
| Seroba Life Sciences | Series A Extension, Series A |
| Earlybird Venture Capital | Series A Extension, Series A, Seed |
| Enterprise Ireland | Seed, Series A |
| HBM Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors increased 32% MoM.
- Mar 17, 2026
Received clearance for device in super-bore aspiration market.
Perfuze Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Perfuze's valuation, stock price, and market status.
Is Perfuze a public or private company?
Perfuze is a private company.
What is the current stock price of Perfuze?
Perfuze is a private company with no public stock price. No recent secondary market data is available.
How much is Perfuze worth (valuation)?
Valuation information for Perfuze is not publicly available.
Can I buy Perfuze stock?
Perfuze shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Perfuze's last funding round?
Perfuze's most recent funding round was Series A Extension on March 13, 2024.
Who are the main investors in Perfuze?
Key investors in Perfuze include EQT Life Sciences, SV Health Investors, Seroba Life Sciences, Earlybird Venture Capital.
Will Perfuze IPO soon?
No public IPO plans have been announced for Perfuze.
How can I track Perfuze secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Perfuze's secondary market activity and sign up for updates.